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nloaded fromCoordinated conformational transitions in oligomeric enzymatic complexes modulate function in response to
substrates and play a crucial role in enzyme inhibition and activation. Caseinolytic protease (ClpP) is a tetra-
decameric complex, which has emerged as a drug target against multiple pathogenic bacteria. Activation of
different ClpPs by inhibitors has been independently reported from drug development efforts, but no rationale
for inhibitor-induced activation has been hitherto proposed. Using an integrated approach that includes x-ray
crystallography, solid- and solution-state nuclear magnetic resonance, molecular dynamics simulations, and iso-
thermal titration calorimetry, we show that the proteasome inhibitor bortezomib binds to the ClpP active-site
serine, mimicking a peptide substrate, and induces a concerted allosteric activation of the complex. The bortezomib-
activated conformation also exhibits a higher affinity for its cognate unfoldase ClpX. We propose a universal allo-
steric mechanism, where substrate binding to a single subunit locks ClpP into an active conformation optimized for
chaperone association and protein processive degradation.http
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Among the most exciting antibacterial drug targets that have emerged
in the past decade is the caseinolytic protease (ClpP) (1). While mostly
studied in Escherichia coli (EcClpP), ClpP is present in a wide range of
bacteria, as well as in mitochondria and chloroplasts. Functionally,
ClpP can be defined as a cylindrical canonical serine protease com-
posed of two stacked rings, each formed by seven subunits that en-
compass a large (300 kDa) proteolytic core (2). This architecture
restricts access to the 14 proteolytic active sites located inside the
barrel and is key for ClpP function. Although ClpP is able to rapidly
hydrolyze peptides, degradation of large proteins requires the pres-
ence of an AAA+ adenosine triphosphatase (ATPase) complex, such
as ClpA or ClpX in E. coli or ClpC in other species. These unfoldases
provide substrate specificity not only by recognizing, unfolding, and
translocating their globular protein substrates but also by opening the
apical gate region of ClpP, which is otherwise blocked by flexible
N-terminal tails.
ClpP protease and its associated chaperones are essential for the
survival or virulence of several bacteria including pathogens such as
Mycobacterium tuberculosis (Mtb) (3), Staphylococcus aureus (Sa)
(4), and Listeria monocytogenes (Lm) (5). In addition, human mito-chondrial ClpP was associated to human acute myeloid leukemia and
obesity (6, 7). Recently, ClpP from Plasmodium falciparum (PfClpP),
the parasite responsible for malaria infection, has also been proposed
as a promising drug target for the control of this disease (8).
The fact that ClpP is a suitable Achilles’ heel for these organisms is
further reinforced by the recent discovery of natural antibiotics that
target ClpP or its co-chaperones. Efficient bacterial killing could be
accomplished either by opening the axial pore of ClpP and activating
unregulated cell proteolysis (9), by blocking ClpP-ATPase interaction
(10), or by specifically inhibiting its chaperones, ClpX (4) or ClpC1 (11).
Despite recent advances in the field, the study and development of
drugs targeting ClpP have been thwarted by the fact that ClpPs from
different species show notable functional differences. For example,
Mtb contains two clpP genes, clpP1 and clpP2, both of which are es-
sential for viability and infectivity (1, 3). Although both genes encode
serine proteases that form heptameric rings, first attempts to express
and characterize isolated MtbClpP1 and MtbClpP2 in E. coli yielded
complexes that lacked proteolytic activity (12, 13). The study of
MtbClpP1P2 was not possible until the finding that a small activator,
derived from classical serine protease inhibitor peptide aldehydes (3),
was required to promote the formation of an active complex composed
of one heptameric ring fromClpP1 and another fromClpP2 (3). Oddly
enough, the small activators were found at the protein active site, and it
is not clear how their presence at the active site can promote activation
rather than classic competitive inhibition (14, 15). Furthermore, several
structures obtained by x-ray crystallography and solution nuclear
magnetic resonance (NMR) studies have suggested that ClpPs, while
keeping a tetradecamer organization, can adopt several conformations
(16, 17). Currently, at least three conformations have been reported: an
extended state (catalytically active), a compressed state (catalytically in-
active), and a compact state (catalytically inactive) (17–19). In addition,
while someClpPs are inherently active, others are purified as non-active
forms (3, 12, 13, 15, 20–22).
Here, we report a study of ClpP from Thermus thermophilus
(TtClpP), which is, as described for other ClpPs, purified in an inactive1 of 18
SC I ENCE ADVANCES | R E S EARCH ART I C L Econformation but can be in vitro activated by small molecules. Using an
integrated approach including multiple biochemical assays, x-ray crys-
tallography, magic angle spinning (MAS) NMR and solution-state
NMR, isothermal titration calorimetry (ITC), and molecular dynamics
(MD) simulations, we show that bortezomib, a boronic acid previously
identified as an inhibitor ofMtbClpP1P2, induces a concerted confor-
mational change in ClpP, resulting in complex activation. On the basis
of our data, and building further upon previously established results, we
propose a universal mechanism for ClpP activation. o
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 RESULTS
Bortezomib in low concentrations activates TtClpP
peptidase activity
Although cellular protein quality control is likely to be particularly
challenging for organisms living at high temperatures, ClpP from
extremophiles remains modestly documented. T. thermophilus (Tt) is a
Gram-negative eubacterium used in a wide range of biotechnological
applications and as a model organism for genetic manipulation, struc-
tural genomics, and systems biology. The bacterium has an optimal
growth temperature of about 65°C. We obtained TtClpP by recombi-
nant expression and purified it as a canonical tetradecamer of around
300 kDa, as monitored by size exclusion chromatography (SEC) and
multi-angle laser light scattering (MALLS) (fig. S1). This tetradecamer
could be reorganized into a smaller heptameric species when ammonium
sulfate (300 mM) was included in the elution buffer, likely as a result
of the disruption of inter-ring salt bridges (fig. S1A). As anticipated,
TtClpP displayed enhanced thermostability compared to previously
studied ClpPs. Using the single tryptophan of the TtClpP monomers
(14 per tetradecamer) as a probe, the melting point (TM) of ClpP was
determined as 84°C (fig. S1C), 30°C above the value reported for S.
aureus ClpP (SaClpP) (23). The increased stability is also reflected in
an elevated optimal catalytic temperature. When we measured the deg-
radation of the green fluorescent protein GFPsrrA by TtClpP in associ-
ationwith the cognateTtClpXATPase, we foundmaximal rates at 60°C
(the highest temperature we could achieve with the fluorimeter equip-
ment; fig. S2, A and B). However, although TtClpP is competent to de-
grade folded substrates in association with TtClpX, it is a rather
inefficient peptidase even at 60°C. In comparison to EcClpP at 37°C,
it has a 200-fold lower specific activity in degradation experiments with
the short tripeptide substrate PKMamc (proline-lysine-methionine-7-
amino-4-methylcoumarin; at a working concentration of 100 mM).
During attempts to identify inhibitors ofTtClpP that could be used
for further structural biology studies, we observed that bortezomib
did not inhibit, but actually stimulated, TtClpP peptidase activity at
concentrations from 3 to 100 mM (Fig. 1A and fig. S3A). Bortezomib
is anN-protected dipeptide with a boronic acid instead of a carboxylic
acid that forms adducts with activated threonines or serines (24). It
was developed as a proteasome inhibitor targeting specifically the
chymotrypsin-like sites of this complex with nanomolar affinity while
exhibiting limited reactivity to the other active sites of the complex. We
selected thismolecule because it was recently identified in an in vivo cell
screen as an inhibitor of GFPssrA degradation by the MtbClpXP1P2
complex and was proposed as a potential antituberculosis candidate
(25). The bortezomib dependence of the TtClpP peptidase activity
displays a bell shape, with maximum activation at 12.5 mM (about
10- to 20-fold activation), while higher drug concentrations reduced
the enzymatic activity (Fig. 1A). A time-lag phase for the activation
of TtClpP was consistently observed and likely resulted from the neces-Felix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019sary fluorimeter temperature equilibrium because the assays were
executed at 45° to 60°C. Bortezomib activation derives from intrinsic
properties ofTtClpP, andwhen tested againstEcClpPpeptidase activity,
it behaved as a powerful inhibitor with an apparent IC50 (median inhib-
itory concentration) of 1.6 mM (fig. S3B).
Although paradoxical, activation of some ClpP complexes by in-
hibitors has already been reported (3, 22, 26–28). Akopian and col-
leagues (3) have shown that the MtbClpP complex (MtbClpP1P2),
otherwise inactive, is activated by small peptide aldehydes. The most
potent of these activators inMtb, an N-terminally blocked dileucine
(Bz-LL), was also capable to activateTtClpP, albeit with lower efficiency
(Fig. 1B). Conversely, bortezomib could also activate the peptidase ac-
tivity of theMtbClpP1P2 complex.We applied a set of biochemical, bio-
physical, and structural studies to understand the mechanistic and
functional foundation of this inhibitor-based activation.
Bortezomib activates TtClpP unfolded protein degradation
After establishing the bortezomib-induced activation of TtClpP for
degradation of small peptides, we investigated its potential to stim-
ulate protein degradation. Contrary to small peptides, which can50
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Fig. 1. Bortezomib activates TtClpP for peptide and intrinsically disordered pro-
tein degradation. (A) TtClpP (1 mM complex) peptidase activity was measured with
the substrate PKMamc (100 mM) in the presence of bortezomib at the indicated con-
centrations. As the peptide is cleaved, 7-amino-4-methylcoumarin is released, result-
ing in an increase in the measured fluorescence. Initial rates are plotted as a function
of the bortezomib concentration. RFU, relative fluorescence units. (B) The activating
effect of bortezomib is compared with the one observed with Bz-LL, a previously
described activator of MtbClpP1P2. (C) The degradation of the unfolded protein sub-
strate FITC-casein by TtClpP (0.1 mM complex) was measured in the presence of the
indicated bortezomib concentrations. Initial degradation rates following temperature
equilibration were plotted as a function of the bortezomib concentration. (D) TtClpP
(1 mM complex) can degrade the intrinsically disordered E. coli FtsZ. The degradation
of FtsZ by TtClpP was monitored by SDS-gel electrophoresis. While no degradation
was observed with apoTtClpP, degradation of FtsZ was observed in the presence of
200 mM and 2 mM bortezomib.2 of 18
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 independently diffuse into the proteolytic chamber, the basal degrada-
tion of proteins by ClpP is low because the flexible N-terminal tails
of ClpP act as a barrier to protein entry into the chamber. Our as-
say used as proteolytic target fluorescein isothiocyanate–labeled casein
(FITC-casein), a proline-rich protein lacking stable secondary struc-
tures. Protease-catalyzed hydrolysis of FITC-casein leads to highly flu-
orescent dye–labeled peptides. Similarly to the peptidase activity,
addition of bortezomib did not result in inhibition of FITC-casein
degradation, but instead, a striking activation was observed (Fig. 1C
and fig. S4A). Furthermore, contrary to what was observed with the
peptidase activity, concentration dependence of this effect was linear and
no reduction of the activation was observed up to 100 mM (Fig. 1C). In
addition to casein, we tested whether bortezomib could also promote
the degradation of other substrates. The bacterial guanosine triphos-
phatase (GTPase) FtsZ forms a cytokinetic ring at mid-cell, recruits
the division machinery, and coordinates membrane and peptidoglycan
cell wall invagination. An FtsZ monomer contains an intrinsically
disordered C-terminal linker, and the degradation of FtsZ by ClpP ac-
tivated by the natural antibiotic acyldepsipeptides (ADEPs) has been
proposed to trigger growth inhibition (29). We therefore tested the ef-
fect of bortezomib ClpP-catalyzed proteolysis on FtsZ and found that
FtsZ was, even at low temperature for TtClpP (37°C), degraded by ClpP
when in the presence of bortezomib (Fig. 1D) (29). These experiments
establish that bortezomib acts as a TtClpP activator for the degradation
of different disordered protein substrates or small peptides.
ClpX enhances peptidase activity of TtClpP
Because ClpP acts in association with specific chaperones in vivo
(ClpX, ClpA, or ClpC), we proceeded by assessing the effect of TtClpX
association on TtClpP peptidase activity. When we measured the deg-
radation of PKMamc byTtClpP in the presence ofTtClpX, we observed
a marked increase in peptidase activity that was dependent on TtClpX
concentration (Fig. 2, A and B). Similarly to TtClpP activation by
bortezomib, a lag phase was observed, which could result either from
temperature equilibrium or from oligomerization of TtClpX hexamers
from monomers in the presence of adenosine 5′-triphosphate (ATP).
Because bortezomib and ClpX are both able to activate TtClpP, we
tested whether the effects of bortezomib and ClpX were synergistic.
Bortezomib (10 mM) did not induce further activation but instead
acted as an inhibitor (fig. S4B) in the presence of ClpX. However, in
the presence of bortezomib, a marked feature of the ClpX activation
curve was a certain level of cooperativity, i.e., less TtClpX concentration
was required to achieve maximal activity, suggesting that bortezomib
binding can modulate the affinity of ClpP for ClpX (Fig. 2B). In the
presence of bortezomib, half-maximal activation was achieved with a
TtClpX6/ClpP14 ratio of 2.4, corresponding to 120 nM TtClpX6. This
value for TtClpX-TtClpP association is on the same order of magnitude
as the one reported for E. coli using an indirect ATPase assay (27).
The large activation of ClpP-catalyzed degradation of small peptides
by ClpX was unexpected, because auxiliary chaperones are required for
unfolding, translocation, and opening of the N-terminal pores facilitat-
ing entry of protein substrates into the ClpP proteolytic chamber, while
small peptides can just freely diffuse into the proteolytic chamber. The
hydrolysis rate of small peptides (dipeptides) in EcClpP has been inde-
pendently shown to be unaffected by ClpX association (30, 31). Activa-
tion by EcClpX is, however, essential for bigger peptides and proteins,
andClpX activation increases as a function of peptidemolecular weight.
ClpX binding has also been shown to stimulate active-site modification
of ClpP by fluorophosphates, but only to the level predicted from fasterFelix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019diffusion of the inhibitor into the ClpP chamber (30). Nonetheless, it
was recently proposed that, in addition to the opening of the ClpP gate,
chaperones can also allosterically activate the ClpP catalytic sites by
inducing a shift of ClpP from the inactive compressed state, in which
the catalytic triad is distorted, to the extended state, in which the cata-
lytic residues are positioned for enzymatic action (23).
Because the small molecular weight of the substrate used in our as-
says is not an obstacle to its free diffusion into the proteolytic chamber
(molecularweight of 574Da) (30), we testedwhetherTtClpX binding to
TtClpP could affect the protease active sites. To confirm the effect of co-
chaperone or bortezomib on the active site, we used an assay based on
fluorophosphonate (FP) conjugated tetramethylrhodamine (TAMRA-
FP,molecularweight of 680Da), which specifically and covalently labels
activated Ser active sites with a fluorescent dye. TAMRA-FP can be used
to quantify the reactivity of a given protease active site, e.g., if the cata-
lytic triad is in the correct geometry for proper serine activation. The
presence of an activated Ser can thus be detected using fluorescent gel
imaging. We incubated TtClpP and TAMRA-FP with either urea, bor-
tezomib, dichloroisocoumarin (DCC; an inhibitor of serine proteases),
or TtClpX. While urea (by unfolding the complex) and DCC (by ir-
reversibly blocking the active site) reduced the amount of TAMRA
bound to ClpP, ClpX association resulted in a significant increase of
active-site acetylation—a clear indication that ClpX association acti-
vates the ClpP active site. Although bortezomib also leads to an activa-
tion of ClpP, we failed to observe any increase of TAMRA-FP labeling
(Fig. 2C). This could result from competition between the two inhibitorsD
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Fig. 2. TtClpX activates TtClpP peptidase activity. (A) TtClpP (0.1 mM complex)
peptidase activity was measured in the presence of TtClpX at the indicated ClpX6/
ClpP14 ratios. (B) The activation of TtClpP peptidase activity in the absence (circles)
or presence (triangles) of bortezomib (10 mM) is plotted as a function of the molar
ClpX6/ClpP14 ratio. Half-maximal peptidase activity was obtained at 6.5 ± 0.5 and
2.4 ± 0.3 ClpX6/ClpP14 ratio for the apo and bortezomib-loaded TtClpP, respectively.
(C) Activation of the TtClpP active site by bortezomib (100 mM) and TtClpX (1 mM),
monitored by labeling with TAMRA-FP. TAMRA-FP (5 mM) was incubated with
TtClpP (1 mg/ml), and aliquots of the reaction mixture were removed at the indi-
cated time points. Labeling of the active-site serines is reflected by the increase in
fluorescence observed.3 of 18
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 (bortezomib and TAMRA-FP). Therefore, we cannot exclude that
TAMRA-FP binding also results in TtClpP activation. However, con-
trary to bortezomib, TAMRA-FP forms irreversible adducts with
TtClpP, thereby preventing activity measurements.
Bortezomib binds to the serine of ClpP active site
To understand bortezomib’s mechanism of action, we examined its
binding site using NMR spectroscopy. With a molecular weight of
300 kDa, NMR studies of TtClpP are challenging. In solution, the
slow tumbling leads to severe line broadening, to the extent that stan-
dard solution NMR studies are not feasible. The most sensitive route
for observing solution NMR signals of proteins of the size of ClpP is
the specific labeling of methyl groups in an otherwise deuterated
background (32). Although being a very powerful approach for probing
interactions and dynamics, methyl-directedNMR is able to observe only
the subset ofmethyl-bearing amino acid types, and the sequence-specific
assignment of NMR resonances is challenging, generally requiring
multiple mutants.
MAS solid-state NMR does not suffer from this inherent size lim-
itation and is able to detect all amino acid types.Wehave used samples
of TtClpP that were either obtained from sedimenting ClpP from so-
lution into MAS NMR sample tubes (1.3-mm rotors) or obtained by
addition of methyl-pentane-diol, an oft-used precipitant in crystallog-
raphy. Spectra acquired from these two preparations are very similar.
We have used proton-detected three-dimensional (3D) and 4D MAS
NMR approaches (33) to obtain the sequence-specific resonance as-
signment for (1HN, 15N, 13Ca, 13CO) nuclei of 97 residues spread
throughout themolecule, including the active site and the central helix
aE, which undergoes most changes in the compressed-to-extended
transition. The N-terminal gate region was not assigned, presumably
due to its structural heterogeneity and dynamics, which lead to in-
efficient NMR coherence transfers and line broadening (16). Figure
3A shows the residue-wise secondary structure obtained from these
MAS NMR resonance assignments. As expected, the location of
secondary structuresmatches well the information inferred from crys-
tallography (see below).
3D spectra correlating intra-residue 1H-13Ca-15N frequencies (re-
ferred to ashCANH)of sedimentedTtClpPwith andwithout bortezomib
are reported in Fig. 3 (B andC). The observed changes aremodest, which
is likely linked to the relatively low affinity of bortezomib, making it
difficult to saturate the protein in the highly concentrated sedimented
sample. Nevertheless, chemical shift perturbations (CSPs) are ob-
served for a number of residues in the vicinity of the active site, includ-
ing Val70, Gly73, Tyr77, and the catalytic Ser97, as well as residues in the
neighboring helix aE (Fig. 3D). These data reveal that bortezomib in-
teractswith the active site, and suggest that the interaction induces also
small changes in the structure and the dynamics of helix aE, which is
involved in mediating the compressed-to-extended transition.
To independently confirm the direct involvement of the active
site for bortezomib binding in solution, we have performed addition-
al NMR experiments, making use of perdeuterated, Ile-d1-CH3–
labeled TtClpP. Spectra of apo TtClpP, and of the latter in the presence
of 2 mM bortezomib, are shown in Fig. 3E (left). Although we did not
attempt to assign the resonances of the 18 isoleucines per ClpP subunit,
the clear differences in the spectra without or with bortezomib un-
ambiguously confirms binding. In a control experiment performed
with the catalytic S97A mutant, no spectral changes were observed,
corroborating that the bortezomib interaction requires the presence
of the catalytic serine (Fig. 3E, right). The absence of any substantialFelix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019CSP in the S97A mutant demonstrates that all spectral changes are a
result of the direct binding of bortezomib to the active site and its
associated conformational changes—not from nonspecific binding
to other parts of the protein.
Together, MAS NMR and solution NMR provide direct evidence
that bortezomib binds to the catalytic site. CSPs outside the active site
(particularly in helix aE) suggest that bindingmay lead to further struc-
tural changes, possibly connected to the observed TtClpP activation.
Structural basis for bortezomib activation
To understand the structural details of the TtClpP-bortezomib interac-
tion initially characterized by NMR, we used x-ray crystallography and
determined the crystal structures ofTtClpP in the absence and presence
of bortezomib at a resolution of 1.95 and 2.7 Å, respectively (Fig. 4).
The overall structure of TtClpP is essentially identical to the “ex-
tended” state (34–37) of ClpP described for other species {root mean
square deviation (RMSD) to EcClpP tetradecamer [Protein Data Bank
(PDB): 6MT6] = 2.115 Å for 1451 aligned Ca atoms and RMSD to
EcClpP monomer = 0.73 Å for 176 aligned Ca atoms}, which is in
agreement with its high sequence similarity to ClpP orthologs (% iden-
tity to EcClpP = 58.25). The structure of one TtClpP monomer is
presented in Fig. 4B and depicts an a/b-fold composed of two domains:
a head domain comprising six repeats of a/b units (helices A to D, F,
and G and strands 1 to 5, 7, and 8) and a handle domain (helix E and
strand 6). The N terminus of TtClpP forms a short antiparallel
b-hairpin that protrudes from the apical surface of the barrel. This
N-terminal b-hairpin is constituted of residues 5 to 8 and residues
15 to 18 of TtClpP, with missing electron density for residues 9 to 14.
While the overall monomer structure of ClpP is highly conserved
among the structures solved to date, a high degree of variability exists
in the conformation of the N-terminal regions. Several ClpP crystal
structures feature N-terminal b-hairpin structures of varying lengths
and degrees of flexibility, some of which appear to be stabilized by
crystal-packing contacts (38). Solution NMR studies have demon-
strated that the N termini of ClpP are structurally heterogeneous
and adopt multiple conformations (16, 39), which might explain the
missing density near the end of the N-terminal b-hairpins in the
TtClpP structure.
Unexpectedly, in the TtClpP crystals without added bortezomib,
we consistently observe a continuous stretch of electron density near
the active-site serine (Ser97) of each TtClpP monomer, which, based
on its shape, suggests the presence of a tripeptide (Fig. 4C and fig. S5).
Because no peptide was added, the nature of this molecule was un-
known. We, therefore, built it in the electron density as a tri-L-alanine
(see also omit and polder maps presented in fig. S5). The presence of
short peptides in Helicobacter pylori ClpP structures resulting from
proteolysis during crystallization has been previously described (40).
While in that particular case the observed tri- and tetrapeptides are
caused by proteolysis of added heptapeptides before crystallization,
the origin of the tripeptides observed in our TtClpP crystals remains
unclear. Matrix-assisted laser desorption/ionization–time-of-flight
(MALDI-TOF) measurements exclude the presence of these peptides
in fresh purified TtClpP. We speculate that they are the result of au-
toproteolysis of unfolded or partially unfolded TtClpP in the crystal-
lization drops followed by the formation of TtClpP:peptide crystals.
The serendipitous presence of peptides near the active-site Ser97 pro-
vides valuable insights into how TtClpP binds its substrates (Fig. 4C,
inset 1). Apart from the active-site Ser97, the terminal carboxy group
of the peptide (residue P3) is further stabilized by hydrogen bonds4 of 18
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 with the Ne2 atom of His122 (part of the ClpP catalytic triad) and the
backbone amide groups of Met98 and Gly68. The Nd1 atom of His122
on its turn forms an additional hydrogen bond with Asp171, the third
residue of the ClpP catalytic triad. The amino groups of peptide re-
sidues P2 and P3 are stabilized by backbone interactions with Gly68
and Trp125, respectively, while the carbonyl groups are stabilized by in-
teractions with amino groups of Trp125 and Val70 (Fig. 4C, inset 1). The
geometry and distances between the catalytic triad residues (Ser97,
His122, and Asp171) are consistent with a functional TtClpP catalytic
triad because their distances are in the range of the ones observed in
classical serine proteases and active ClpPs (40). Figure 4B displays
the 2.7-Å resolution structure of the bortezomib-bound state (see also
fig. S5). Similarly to the peptides present in the TtClpP:peptide struc-
ture, bortezomib tightly fits between b-strand 6 and a small b-turn
formed by Gly68 and Val70, thereby forming an antiparallel b-sheet.
This conformation is characterized by a hydrogen bond network al-
most identical to the one observed in the TtClpP:peptide interaction
(Fig. 4C, inset 2). Unlike the TtClpP:peptide complex, where Ser97 is
forming hydrogen bonds with the terminal carboxy group of the pep-
tide, bortezomib seems to be covalently bound to the active-site Ser97
via its boron atom. Other significant differences are observed in the
conformation of Trp125, which is displaced toward bortezomib and
forms an aromatic interaction with the bortezomib phenylalanyl group.
In addition, the nearby Thr131 residue, which in peptide-bound TtClpP
interacts with Arg170 of a neighboring ClpPmonomer, now forms a hy-
drogen bond with Gln123 of an opposing ClpP monomer in the other
heptameric ring. Despite the rearrangement of the Trp125 side chain, the
catalytic triad geometry is again consistent with a fully active protease.
To probe the flexibility of TtClpP, we used MAS NMR spin relaxa-
tion experiments and MD simulations. Site-specific amide 15N R1r
experiments probe the local amplitudes and time scales of backbone
motion and are particularly sensitive to nanosecond-to-millisecond
motions (41). The sites with highest 15N R1r rate constants are found
not only in the loop regions but also at the tip of helix aE (Fig. 4, D and
E).One-microsecond-longMD simulations of theTtClpP tetradecamer
in the apo and peptide-bound states corroborate this observation, albeit
with a greater flexibility at the tip of the helix (Fig. 4, F andG). Enhanced
flexibility in this helix has been reported also in EcClpP by methyl-
directed solution-state NMR and suggested by other methodologies
(16–19, 34, 35). Because of the lack of reliable parametrization of the
boronic acid moiety of bortezomib, we focused on simulating tripep-
tides bound to the active site. It is noteworthy that over the length of
three independent simulations of ClpP initially loaded with tri-alanine
at all active sites, only a fourth of the peptides remain associated to their
designated active sites (fig. S6), consistent with the idea that the
products of TtClpP are necessarily weak binders, which ought to be re-
leased rapidly to leave the catalytic sites ready for the next degradation
reaction.
Bortezomib induces the transition from a tense state to a
relaxed state with higher affinity for the substrate
Having identified the bortezomib-binding site of TtClpP by NMR
and x-ray crystallography, we turned to ITC to characterize thermo-
dynamically the interaction at different temperatures ranging from
25° to 45°C. At 25°C, far from the ideal catalytic temperature of
TtClpP (65°C), only a moderate affinity and symmetric binding iso-
therm was observed. The binding enthalpy was negative and rather
small (see Table 1), thus indicating that binding was mainly entropy-
driven. However, when the temperature was increased to 35° and 45°C,Felix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019considerable changes were observed in the binding isotherm. The
asymmetry of the curve and the appearance of two different phases
in the binding isotherm along the titration, within the low ligand satu-
ration region, were clear indicators of positive cooperativity (Fig. 5A).
Because of the architecture ofTtClpP, comprising two heptameric rings
forming a tetradecameric assembly, the ITC data were fitted to the
Monod-Wyman-Changeux (MWC) model (Fig. 5B), which considers
two intrinsically noncooperative conformations, with low and high
binding affinity, denoted as tense (T) state and relaxed (R) state, respec-
tively. In theMWCmodel, ligand binding shifts the equilibrium toward
the high-affinity conformation (R) in a concerted cooperative way (i.e.,
all subunits change their conformation simultaneously; Table 1). This
model has been previously transposed to other enzymatic systems,
where activation at low ligand concentration and inactivation at high
ligand concentration were also observed (42).
Fitting of the ITC data revealed that in the absence of the ligand,
76% of TtClpP exists in the T state, which has a lower affinity for
bortezomib (Kd,T = KT
−1 = 40 mM). Bortezomib binding induces a
concerted transition from the T state to the R state, with a higher affinity
for substrate (Kd,R = KR
−1 = 15 mM). A model in which we assumed
that there is no ligand binding to the subunits in the T conformation
(KT = 0, DHT = 0) can be ruled out based on significantly worse
fitting. The higher affinity of the ligand for the R conformation drives
the conversion of T subunits into R subunits. In addition, the compul-
sory concerted conformational change within a given protein oligomer
(i.e., all subunits in a given protein oligomer must undergo the confor-
mational change at once, even if not all of them are occupied by ligand)
will further promote the conversion of T subunits into R subunits,
thereby increasing the total fraction of R subunits. The Hill coefficient
[maximal slope in the log(nLB/(14 − nLB)) versus log[ligand] plot] of
TtClpP is 1.3, which is rather small for a tetradecameric protein but
was expected considering the small value for the conformational
equilibrium constant g.
Although theMWCmodel was used 40 years ago for the calorimet-
ric study of the interaction of trout hemoglobin with carbon monoxide
using a gas-liquid reaction calorimeter (43), the present work represents
the first detailed mathematical description and implementation of the
MWCmodel in ITC, for which the experimental methodology and the
mathematical formalism are not the same as those outlined in the afore-
mentioned seminal work.
The MWC model provides a rationale for TtClpP activation by
bortezomib. Activation of TtClpP by the inhibitor bortezomib atTable 1. Thermodynamic parameters of bortezomib binding from ITC
and fitting to the MWC model. KR and KT refer to the bortezomib as-
sociation constants for the relaxed and tense state. DHR, DHT, and DHg
refer to the binding enthalpy of the R state, T state, and conformational
enthalpy between R and T conformations. g is the equilibrium constant
between R and T conformations in the absence of the ligand. N is the
fraction of active or binding-competent protein. Relative errors in equi-
librium constants are 30%. Absolute error in enthalpies is 0.3 kcal/mol.T (°C) N KR
(M−1)DHR
(kcal/mol)KT
(M−1)DHT
(kcal/mol)g DHg
(kcal/mol)25°C 0.97 4.5 × 104 −0.5 No apparent cooperativity35°C 0.97 8.0 × 104 −0.9 2.8 × 104 −0.1 3.3 −0.345°C 1.00 6.5 × 104 −1.5 2.5 × 104 −0.3 3.2 −0.27 of 18
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Fig. 5. Cooperative bortezomib binding detected by ITC experiments. (A) Calorimetric titrations for the interaction of TtClpP (10 mM in the calorimetric cell) with
bortezomib (1.4 mM in the injecting syringe) in 50 mM Hepes (pH 7.6) and 50 mM NaCl. Experiments were performed at three different temperatures: 25°, 35°, and 45°C.
Thermograms (thermal power as a function of time) are displayed in the upper plots, and binding isotherms (ligand-normalized heat effects per injection as a function
of the molar ratio, [L]T/[P]T) are displayed in the lower plots. The binding isotherms were analyzed with the MWC model for TtClpP, consisting of 14 identical subunits,
each one containing a single ligand-binding site. Nonlinear least squares regression analysis allows the determination of the following binding parameters (see Table 1):
association constants for the R and T states (KR, KT), binding enthalpies to the R and T states (DHR, DHT), conformational equilibrium constant and conformational
enthalpy change between states R and T (g, DHg), and fraction of active protein (N). (B) MWC model for a 14-mer oligomeric protein. The protein can populate only
two conformational states in equilibrium (with equilibrium constant g): all subunits in R (relaxed, ellipsoidal shape) conformation or all subunits in T (tense, spherical
shape) conformation. Subunits have a single ligand-binding site, exhibiting the R conformation a higher binding affinity (KR > KT). Ligand binding occurs through an
independent (noncooperative) fashion within an oligomer (ligand-free subunits in light blue and ligand-bound subunits in dark blue). T conformation is favored at low
ligand concentration; the higher ligand-binding affinity for R conformation promotes a highly cooperative compulsory concerted conformational change driven by
ligand binding and involving all subunits within an oligomer, displacing the equilibrium toward the R conformation. (C) Molar fraction of the different protein species
(total, ligand-free, and ligand-bound R and T conformations) as a function of ligand concentration: total fraction of subunits in R conformation (continuous black line),
total fraction of subunits in T conformation (continuous red line), fraction of subunits in ligand-bound R conformation (dashed black line), fraction of subunits in ligand-
bound T conformation (dashed red line), fraction of ligand-free subunits in R conformation (dotted black line, highlighted with an arrow), and fraction of ligand-free
subunits in T conformation (dotted red line). In addition, the fraction of ligand-bound subunits in either R or T conformation is shown (dashed green line). It is obvious
that the contribution of subunits in T conformation to the ligand binding is very small (dashed red line). At very low ligand concentration, 77% of the protein subunits
are in T conformation and 23% are in R conformation, according to the value of the equilibrium constant g equal to 3.3. At low ligand concentration, the total fraction of
subunits in R conformation increases, while the total fraction of subunits in T conformation decreases due to the T→R conversion. However, both the fractions of
ligand-bound subunits in R and T conformation increase due to ligand binding (although the increment in ligand-bound subunits in T conformation is negligible). At
high ligand concentration, the total fraction of subunits in R conformation further increases, while that of total subunits in T conformation decreases, and the fraction of
ligand-bound subunits in R conformation further increases due to ligand binding, but the fraction of ligand-bound subunits in T conformation decreases due to the
T→R conversion. The fraction of ligand-free subunits in R conformation dominates this region, with a maximal population of 60%. This is due to the concerted con-
version of subunits within a given protein oligomer (all subunits within an oligomer undergo the conformational change T→R, although not all of the subunits bind a
ligand). At very high ligand concentration, the fraction of ligand-bound subunits in R conformation dominates the conformational ensemble, reaching a maximal
population of 100%. The R↔T equilibrium shows a switchover or crossover point (R and T are equally populated) at around 2 mM free bortezomib concentration.
(D) TtClpP (1 mM complex) peptidase activity was measured as a function of PKMamc concentration in the presence (15 mM) and absence of bortezomib.Felix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019 8 of 18
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 moderate concentrations occurs as a consequence of the concerted
conformational change within the protein tetradecamer, which makes
the total fraction of subunits in the enzymatically active R conforma-
tion (FR,Total) much larger than the fraction of ligand-bound subunits
in R conformation (FR,Bound), i.e., there is no proportionality between
FR,Total and FR,Bound (Fig. 5C). At intermediate bortezomib concentra-
tion, the fraction of inhibitor-free (active) subunits in an R confor-
mation is maximal and predominates in the speciation distribution
(Fig. 5C). Thus, the extents of cooperativity for binding and coop-
erativity for activity are different [a phenomenon previously reported
for allosteric proteins in (44)]. If the conformational changes were not
concerted, then the activity of TtClpP would continuously decrease
with increasing bortezomib concentration, with no maximal activity
at intermediate bortezomib concentration. The increase in the fraction
of inhibitor-free R subunits at moderate inhibitor concentration is the
molecular event underlying the increase in activity. Similarly, the de-
crease in the fraction of inhibitor-free R subunits at high inhibitor
concentration is the molecular event underlying the decrease in activ-
ity at high inhibitor concentration.
The ITC-derived model predicts accurately the activity data. Ac-
cording to the peptide degradation activity measurements (Fig. 1A),
the maximal TtClpP activity is found around 12.5 mM of total borte-
zomib. The ITC-derived MWC model predicts that the maximum
fraction of inhibitor-free TtClpP in the R conformation (FR,Free)
should be around 6 mM of free bortezomib (Fig. 5C). Considering
the population of bound TtClpP at 6 mM free bortezomib concentra-
tion (FTorR,Bound = 0.3; Fig. 5C), and taking into account the TtClpP
subunit concentration of 10 mM(used in our activity measurements),
one can calculate that the concentration of bortezomib bound to
TtClpP is 3 mM.Consequently, the total concentration of bortezomib
for achieving 6 mM free bortezomib (i.e., the concentration for max-
imal bortezomib-free subunits in R conformation) is around 9 mM,
in excellent agreement with the activity measurements reporting a
maximum activity for 12.5 mM bortezomib concentration (Fig. 1A).
Furthermore, to verify that the bortezomib-induced R state has a
higher affinity for the substrate, we measured peptide hydrolysis as a
function of substrate concentration in the apo state and in the presence
of nonsaturating concentrations of bortezomib (15 mM). While there
are differences between Kd, a thermodynamic equilibrium constant,
versus a purely kinetic constant as KM, in the presence of bortezomib,
TtClpP displayed an apparent KM around 400 mM. In its absence, no
indications of substrate saturation were observed (Fig. 5D), reflecting
the major differences between the bortezomib-bound and apo states.
Put together, the activity measurements and ITC data reveal that acti-
vation of TtClpP by an inhibitor is achieved by shifting the conforma-
tional population toward a higher-affinity R state.
Off-equilibrium MD simulations provide rationale for
stabilization of extended state
Activity measurements, ITC data, x-ray structures, and NMR spec-
troscopic data have established that, by binding to a subset of TtClpP
active sites, bortezomib and peptide substrates favor a catalytically
more active particle by keeping both the bound and free subunits
in an active state, with the catalytic triad poised for catalysis. We at-
tempted to bridge the functional and thermodynamic information
from biochemistry and ITC with the structural view by performing
in silico experiments. In a nutshell, in these MD simulations, we in-
vestigated the energetics of the transition from the extended (active)
to the compressed (inactive) state and interrogated whether the pres-Felix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019ence of a molecule bound to the active site alters the relative stability
of the two states. Near-equilibrium MD experiments were performed,
in which the two heptameric rings were slowly brought from the
extended state to the compressed state using the centers of mass of
the two rings as single variable for the steered MD protocol (see
Materials andMethods). Figure 6 (A and B) displays the force required
for this extended-to-compressed transition, obtained from five inde-
pendent in silico experiments, as a function of the distance of the two
half-rings. Figure 6B shows the work (i.e., the integrated force) for this
process. The present simulations have been performed for both the apo
state (gray) and a substoichiometrically peptide-loaded state in which
only 2 or 3 of the 14 binding sites were occupied with tri-alanine pep-
tide. During the compression process, none of the initially bound pep-
tideswere expulsed from their target catalytic sites, and all the secondary
structure elements were preserved (Fig. 6, C to E). Compressing ClpP
from the extended conformation requires a stronger force in the pres-
ence of a substoichiometric amount of alanine tripeptides compared to
the empty protein (Fig. 6, A and B).
Together, these data provide a rationale for the enhanced stability
of the extended conformation in the presence of a ligand: Even sub-
stoichiometric amounts of the ligand, i.e., only partially occupied
sites, lead to an overall stabilization of all subunits in the active state.
The simulations were performed with peptides rather than bortezomib
due to the lack of reliable force field parameters for boronic acid and
reveal the substrate-induced stabilization of the active extended
state. It can be expected that this stability difference of extended over
compressed state is even more pronounced with the covalently bound
bortezomib.
The MD simulations support the idea that bound ligand, even at
substoichiometric amounts, favors a stable extended form, which we
believe is the R state modeled in the ITC data, while the apo state is a
compressed state.We attempted to validate the compressed-to-extended
state transition observed from the MD experiments by performing
dynamic light scattering (DLS). Figure 6G shows the hydrodynamic
radii (Rhyd) ofTtClpP in the absence and presence of 5mMbortezomib,
revealing that addition of bortezomib causes an increase of approxi-
mately 8 Å in Rhyd (or 16 Å in diameter) of TtClpP. The experimen-
tally obtained hydrodynamic radii for TtClpP without and with 5mM
bortezomib (5.95 and 6.67 nm, respectively) are in excellent agree-
mentwith the theoretical hydrodynamic radii obtained for compressed
and extended states of ClpP, supporting the view that the T-to-R
transition modeled from the ITC data corresponds to a compressed-
to-extended transition.DISCUSSION
Activation of different ClpPs by previously identified inhibitors has
been independently reported (3, 22), but to date, no mechanism for
these paradoxical results has been proposed. Bortezomib, just like
N-blocked peptide aldehydeMtb activators reported previously, does
not follow the canonical definition for an allosteric activator, i.e., they
bind to the protease active site (14, 15) and their effect is not univer-
sal to all ClpP homologs. For instance, we show here that although
bortezomib activates TtClpP (up to 100 mM), it is, in the same con-
centration range, a good inhibitor of EcClpP. This result is rather
puzzling, considering the high sequence and structural similarity be-
tween the two proteins (58% sequence identity).
We show in the present contribution that ClpP activation by in-
hibitors derives from the intrinsically cooperative character of the9 of 18
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 ClpP tetradecameric structure. Bortezomib, although blocking a num-
ber of active sites, can overall increase the catalytic rate by promoting a
concerted transition in the complex, stabilizing the active-state con-
formation. In line with this observation, the near-equilibrium MD
simulations performed in our study suggest that compression of the
extended-active conformation of TtClpP is hampered when a frac-
tion of the catalytic sites is occupied by unspecific tripeptide substrates.
In the presence of a stronger specific binder such as bortezomib, it could
be reasonably anticipated that compression toward the inactive con-
formation is even more hindered. A comparable mechanism likely
underlies MtbClpP1P2 activation, because it has been shown that
the peptide activator would sterically clash with a non-active ClpP1
complex, thereby forcing the complex into an active conformation (22).
The similarity between the bortezomib TtClpP structure and the
structure of TtClpP with peptides in the active site strongly suggests
that our findings reflect an inherent substrate-dependent activation
mechanism of the enzyme. Through this mechanism, the presenceFelix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019of the substrate in the ClpP active site promotes the activation of the
remaining subunits, allowing efficient and processive protein degra-
dation. Although we were unable to obtain a crystal structure of apo
TtClpP, the DLS experiments performed here are consistent with a
bortezomib-induced transition from a compressed or compacted state
to an extended TtClpP conformation. Addition of bortezomib altered
chemical shifts in MAS NMR experiments, possibly pointing also
toward the changes in the equatorial region of ClpP, expected for a
compressed/extended transition (Fig. 3D).
Our results also support the previously described bidirectional
cross-talk between chaperone binding and protease active sites
(14, 22, 23, 26–28), because bortezomib is no longer an activator in
the presence of the co-chaperone TtClpX and TtClpP partially
saturated with bortezomib binds strongly to TtClpX. Significant dif-
ferences were observed between the activation of TtClpP peptidase
activity and proteolytic activity by bortezomib. While peptidase ac-
tivation displayed a bell-shaped curve, protease activation showed a−8 −6 −4 −2 0
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Fig. 6. In silico pulling experiment of TtClpP from the extended state to the compressed state. (A and B) Profile of the force (A) and work (B) required for
compressing the two rings toward each other as a function of the distance z between the rings (shown in the inset, with exaggerated distance for better visibility).
Three independent 200-ns simulations were performed for apo TtClpP or TtClpP, in which 2 or 3 of the 14 binding sites were occupied with trialanine peptide (see
Materials and Methods). (C and D) Conformations of TtClpP extended (C) and SaClpP compressed (PDB: 3QWD) (D) states observed in crystal structures. (E) Starting
conformation of TtClpP in the steered MD simulations (shown as sphere representation). (F) Final conformation of the compressed state at the conclusion of the steered
MD. Note that the peptides are still bound and that the structure is in good overall agreement with the compressed state from x-ray diffraction shown in (D). (G) DLS
analysis of TtClpP (3 mM) supplemented without or with 5 mM bortezomib. The upper graph shows one representative curve of three replicates measured at 25°C for
TtClpP without (red curve) or with 5 mM bortezomib (green curve), with the relative intensity (in %) plotted versus particle size [hydrodynamic radius, Rhyd (in nm)]. The
average of the three replicates is indicated using a dotted line. The lower graph depicts average hydrodynamic radii (Rhyd) calculated from three independent
experiments measured at 25° and 45°C (0 mM bortezomib, 25°C: 5.946 ± 0.036 nm; 0 mM bortezomib, 45°C: 5.940 ± 0.102 nm; 5 mM bortezomib, 25°C: 6.673 ±
0.192 nm; 5 mM bortezomib, 45°C: 6.702 ± 0.176 nm). Theoretical calculated hydrodynamic radii of compressed TtClpP (6.05 nm) and the extended TtClpP:bortezomib
complex (6.47 nm) are indicated using a dotted black line (see also Materials and Methods).10 of 18
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 linear rise in the range of the used bortezomib concentration. Al-
though the process underlying bortezomib activation in the two ac-
tivities should be common, important differences exist between the
two assays. Protein degradation is strictly dependent on substrate
access to the proteolytic chamber, because larger substrates cannot
diffuse freely toward the proteolytic chamber. Our results showing
protein degradation activated by bortezomib demonstrate that mod-
ulation of protein entry can also be achieved via binding to the ClpP
active site and not exclusively by ClpX or ADEP binding. Protein
access to the proteolytic chamber leads to high local concentrations
of the substrate present at the ClpP active sites. Although bortezomib
activates protein degradation at low concentrations, it must compete
with high concentrations of substrate in the proteolytic activity as-
say, thereby rationalizing the requirement for higher concentrations
of drug to achieve activation. The range of bortezomib concentrations
used in our proteolytic activity assay likely corresponds to the rising part
of the bell curve monitored in the peptidase activity assay and also ex-
plains why several ClpP inhibitors are 10-fold more potent in peptidase
assays compared with protease assays (45).
It is unclear why the action of bortezomib and activators is not
uniformly conserved between different ClpPs. Differences in enzymat-
ic activity are generally more difficult to decode than major structural
differences because allosteric pathways often result from subtle changes
in conformational dynamics that affect population distributions, which
are not readily observed from comparisons of structures. For example,
single mutations or truncations in EcClpP N-terminal have been
shown to induce reversible inactivation of ClpP (16), and using an in-
direct methodology based on the association of an EcClpP E14Wmu-
tant with EcClpA, the equilibrium constant between an EcClpP active
state (R) and inactive state (T) was previously quantified as Keq = 7.5
(37°C) (46), i.e., a value similar to the one we describe here for TtClpP
Keq = 3.3 (45°C). This finding is particularly interesting, as it suggests
that in the absence ofmutations, EcClpP preferentially populates active
states, while TtClpP is preferentially inactive (16). The energy barrier
between the two states is, however, rather small, with an energy gap of
0.7 kcal/mol between the R and the T conformations in TtClpP. Given
the high sequence identity between EcClpP and TtClpP, the key to the
difference in the equilibria between active and non-active states must
necessarily result from small sequence changes. EcClpP and SaClpP
contain a conserved Q131XT/S133 motif at the tip of the turn between
helix aE and the b-strand 6 in the handle domain (fig. S7). Here, Gln131
engages in hydrogen bonds with the h1 and h2 nitrogens of Arg170 on a
neighboring subunit of the same heptamer ring (intra-ring) and with
the backbone oxygen of Glu169 and e1 oxygen ofGln123 on amonomer
of the other ring (inter-ring). The side chain of the conserved Thr133
forms hydrogen bonds with the nitrogen atoms of Gln123 and Lys146
(inter-ring). Gln123 is part of the conserved His-Gln-Pro (HQP) motif,
which includes the catalytic triad His122, while Arg170 is the vicinal
residue of the catalytic triad Asp171. It is clear that this extended hydro-
gen bond network restricts the degrees of freedom of the aforemen-
tioned catalytic triad residues. It is noteworthy that these residues are
conserved neither in TtClpP nor in MtbClpP1. In TtClpP, Gln131 is
replaced by a threonine (Thr131), which interacts either with the e1 ni-
trogen of Arg170 (intra-ring) or with Gln123 (inter-ring) in the TtClpP:
peptide orTtClpP:bortezomib structures, respectively. Ser133 ofTtClpP
contacts Gln123 and Lys146 (inter-ring) in a similar way as EcClpP
Thr133 (fig. S7). The replacement of the conserved glutamine Q131
by the shorter threonine in TtClpP or serine in MtbClpP1 leads to
modifications in the hydrogen network that normally sustains theFelix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019extended helix aE. Structural and MD studies in SaClpP have shown
that these key residues are essential for keeping the long helix aE in a
straight conformation. In TtClpP, the exclusive hydrogen bond accep-
tor character and shorter side chain of Thr131 does not allow the for-
mation of a network that simultaneously coordinates two of the
members of the catalytic triad. This reduced H-bonding capacity is
expected to result in an increased flexibility in that region and likely
to an equilibrium shift toward nonfunctional conformations,
supported by the flexibility measurements reported here by MAS
NMR and MD simulations (Fig. 5). We propose that bortezomib
binding through preferential stabilization of the active site (R form)
shifts the entire population toward a fully active enzyme.
A different hydrogen bond network is also observed forMtbClp1.
In this case, Gln131 is replaced by serine, while Thr133 is replaced by
alanine. When purified alone, ClpP1 is an inactive enzyme, and the
x-ray structure of the ClpP1 tetradecamer shows that the catalytic triad
is not in the active state (13). However, in complex with ClpP2, ClpP1
has been shown to be fully active, likely because MtbClpP2, which
contains the conserved QFTmotif at the tip of the helix aE, can stabilize
ClpP1 by forming a similar network, as has been observed inEcClpP (3).
Cooperativity allows multimeric systems to adapt rapidly to envi-
ronmental changes by more efficiently converting a biochemical input,
i.e., the substrate/ligand concentration, into a biochemical response.
Cooperative response to incoming substrates has been reported for
othermachineries of the protein quality control system. Because protein
degradation is key to cell homeostasis, several levels of regulation have
evolved to prevent uncontrolled proteolysis that would be deleterious to
the cell. ClpP, as well as other complexes like the 20S proteasome, hides
their active sites inside an inaccessible catalytic chamber to prevent un-
controlled proteolysis. This architecture is fine-tuned by ClpP-specific
co-chaperones, which add another layer of regulation in protease con-
trol, either by “opening” the axial pores of the cylinder and translocating
unfolded substrates into the chamber or by directly activating the ClpP
active sites (2). Several studies have reported that ClpX is able to revert
the conformational inhibition of ClpP induced by chemical compounds
(14) or even by mutations known to promote ClpP inactive states (23).
The fact that one of these inactive-state promoting mutations, namely,
the Asp172Asn SaClpP mutant, corresponds to the native form of
LmClpP1 and several other ClpPs suggests that this mechanism could
be relevant for in vivo ClpP regulation in these species (47). Our data
support a similar mechanism of conformational control for TtClpP.
Our observation thatTtClpX and EcClpX (data not shown) can activate
TtClpP further suggests that this enzyme is conformationally attenu-
ated, i.e., in the absence of the chaperone, it is in a latent inactive state.
The nonphysiological activation observed with bortezomib is both a
consequence of the inherent cooperativity of the protease and the fact
that, in the absence of activators, its predominant state is the non-active
T state (Fig. 5C). The small molecule–induced conformational shift
opens new possibilities for drug development, particularly as not only
peptide degradation but also protein degradation is stimulated, as we
report here (Fig. 1C).
In summary, using a host of biochemical, biophysical, and struc-
tural approaches, we have proposed a mechanism for the activation
of ClpP by inhibitors with a key element, namely, a concerted acti-
vating conformational change in the supramolecular ClpP tetradeca-
meric structure elicited by the binding of inhibitors at subsaturating
concentrations. Hints to a similar allosteric behavior have been re-
ported for the proteasome in the presence of bortezomib (47). While
bortezomib inhibits efficiently the chymotrypsin site of the proteasome,11 of 18
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 MATERIALS AND METHODS
Cloning and mutagenesis
TtClpP DNA was directly amplified from T. thermophilus HB8 DNA
and cloned in to a pET41c (Novagen) expression vector using Ned I
and Xho I restriction enzymes. The expressed gene contained the ad-
ditional residues LEHHHHHHHH at its C terminus to allow affinity
chromatography purification. Full-length ClpX DNA was first cloned
into a pET28 vector using Ned I and Hind III restriction enzymes, re-
sulting in residuesMGSSHHHHHHSSGLVPRGSHadded to theN ter-
minus. While full-length ClpX was insoluble, similar to ClpX orthologs
from other species, removal of its N-terminal domain (residues 1 to 54)
allowed expression of a soluble ClpX construct (DTtClpX) (48). Re-
moval of the TtClpX N terminus was performed by GeneCust using
Ned I and Hind III as restriction enzymes. TtClpP and DTtClpX were
expressed in E. coliBl21RIL cells following overnight expression at 20°C
after induction with 1 mM isopropyl-b-D-thiogalactopyranoside
(IPTG). A TtClpP mutant containing an S97A mutation was con-
structed using the QuikChange II Site-Directed Mutagenesis Kit from
Thermo Fisher Scientific.
Protein purification
GFPssrA was purified as previously described (49). Casein FITC
from bovinemilk was obtained from Sigma (C0528) and loaded onto
aG25 column (GEHealthcare) to remove free fluorescein (49).TtClpP
and DTtClpX were purified using native NiNTA (nickel-charged
nitrilotriacetic acid) affinity chromatography followed by SEC
using a 16/600 S200 200 pg Superdex column and a final SEC buffer
containing 100 mM tris (pH 8.5), 100 mM NaCl, and 5% glycerol.
U-[2H,15N],Ile-d1-[13CH3]TtClpP was expressed as described (33).
When expressed in D2O, TtClpP was insoluble and the protein was re-
covered from E. coli inclusion bodies using denaturing conditions.
Briefly, cells were harvested and resuspended in denaturing buffer
containing 8 M urea followed by sonication and centrifugation to re-
move cell debris. The resulting supernatant was loaded onto a NiNTA
column and washed several times with denaturing buffer. The column
was then equilibrated in refolding buffer [100 mM sodium phosphate
(NaPi) (pH 8), 5% glycerol, and 100mMNaCl] followed by elutionwith
elution buffer [100 mM NaPi (pH 8), 5% glycerol, 100 mM NaCl, and
400mM imidazole]. The eluted fractions were loaded into a 16/600 S200
200pg Superdex column, and the fractions corresponding to nativeClpP
were pulled. EcClpP was purified as described in (50). FtsZ was a gift of
T. Hosek and was purified as previously described (50).
Biochemical assays
Concentrations of ClpP and ClpX were calculated using the molec-
ular weight of a tetradecamer and a hexamer, respectively. PKMamc
degradation by TtClpP and EcClpP was measured as described (45).
Briefly, TtClpP in Hepes buffer [50 mMHepes (pH 7.6) and 50 mM
NaCl] was mixed with indicated concentrations of PKMamc and
bortezomib/Bz-LL [or respective dimethyl sulfoxide (DMSO) volume]
at 60°C (or indicated temperature), and fluorescence (340-nm excita-
tion, 462-nm emission) was measured at defined time intervals.
FITC-casein degradation by TtClpP was measured as described (45);
in a typical assay, FITC-casein (0.15 mM) was mixed with TtClpP14
(0.1 mM) and fluorescence increase (440-nm excitation, 509-nm emis-Felix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019sion, 495-nm cutoff) was monitored. GFPssrA (0.5 mM) degradation
by TtClpX6 (0.2 mM) and TtClpP14 (0.1 mM) in the presence of ATP
(10 mM) was monitored, taking advantage of the intrinsic fluores-
cence of GFPssra (440-nm excitation, 509-nm emission, 495-nm
cutoff) at the indicated temperatures. FtsZ degradation by TtClpP
was measured at 37°C. Briefly, TtClpP14 (1 mM)was mixed with pur-
ified FtsZ (20 mM) in the presence of the indicated concentrations of
bortezomib. Aliquots were removed at the indicated time points, and
the samples were loaded in a 15% SDS agarose gel. It is important to
note the substantial differences in TtClpP concentration used for the
different techniques, with 10-fold more protease being used for the
FtsZ protein degradation study compared with FITC-casein degrada-
tion, as a consequence of the lower sensitivity of SDS–polyacrylamide
gel electrophoresis staining versus fluorescein fluorescence methods.
TtClpP reaction with ActivX TAMRA-FP was executed according to
the manufacturer’s instructions (Thermo Fisher Scientific). TtClpP14
(1 mg/ml) was incubated in the indicated conditions with 1 ml of
TAMRA-FR reagent (final concentration of 5 mM). At defined time
intervals, aliquots were removed and loaded in a 4 to 20% SDS gel.
Gels were visualized in a Bio-Rad ChemiDoc XRS system. TtClpP
(20 mM) unfolding was measured in a Varian Cary Eclipse spectro-
fluorimeter monitoring tryptophan intrinsic fluorescence (280-nm ex-
citation, 350-nm emission). TtClpP14 analytical SEC was performed
using a Superdex 200 10/300 GL column.
NMR experiments
MAS solid-state NMR experiments were performed on a Bruker
Avance III spectrometer with a 1.3-mm MAS NMR probe tuned
to 1H, 13C, 15N and 2H frequencies at a MAS frequency of 55 kHz
and an effective sample temperature of 30°C. Backbone resonance
assignment was achieved with proton-detected triple-resonance
experiments described earlier (33). The assignment was obtained
for 97 residues; many more spin systems were observable in the
spectra, but spectral overlap challenged further assignment, which
likely requires additional high-dimensional experiments. Given that
in the present context we were interested in probing interactions and
dynamics, the current extent of assignment was sufficient here.
For the measurement of CSPs upon addition of bortezomib, we
prepared two samples of U-[2H,13C,15N]–labeled ClpP in H2O-based
buffer [100 mM tris (pH 8.5), 5% glycerol, and 100 mM NaCl] con-
taining either 10 mM bortezomib and 5% DMSO or only 5% DMSO.
In both cases, the protein (10 mg/ml) was sedimented into a 1.3-mm
Bruker MAS NMR rotor, and hCANH spectra were collected in ca.
2.5 days per spectrum. The peak positions in the two spectra were
extracted for all assigned backbone sites using CCPN (Collaborative
Computing Project for NMR) software (51).
Spin relaxationmeasurements (15NR1r) were performedwith proton-
detected 3D hCANH experiments. The 3D approach was chosen to re-
solve sites that would be overlapped in 2D 1H-15N correlation spectra.
The experiment comprised a 15N spin-lock element of 15-kHz radio-
frequency field strength and delays of 2 and 55 ms. Total experimental
times were 3 days per 3D experiment. All spectra were acquired with
TopSpin v3.5 and analyzed with CCPN. Relaxation rate constants were
obtained using in-house written Python scripts using the peak intensities
extracted from the 3D spectra, and error bars were determined using
Monte Carlo analysis based on the spectral noise level (determined
in CCPN).
Solution-state NMR experiments were performed on a Bruker
Avance III spectrometer, equipped with cryogenically cooled TCI12 of 18
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 probeheads, operating at a magnetic field strength corresponding to
1H Larmor frequencies of 700 MHz. The sample temperature was set
to 60°C, and 2D SOFAST-methyl-TROSYNMR experiments were re-
corded with an adjusted duration depending on the final concentration
of the proteins (experimental time ranging from 10 to 120min per sam-
ple) (52). The angle of the proton excitation pulse was set to 30°, and the
recycling delay was optimized to 0.6 s to achieve the highest sensitivity
(51). U-[2H,15N],Ile-d1-[13CH3]TtClpP andU-[
2H,15N],Ile-d1-[13CH3]
S97ATtClpP (250 mM) were mixed with 2 mM bortezomib (or DMSO
equivalent) in tris buffer [100mM tris (pH 8.5), 100mMNaCl, and 5%
glycerol].
Crystallization of TtClpP and the TtClpP:
bortezomib complex
Crystallization trials were set up manually in a sitting drop vapor
diffusion setup using 24-well sitting drop plates (Hampton Research)
with drop volumes of 1 ml (0.5 ml of protein solution + 0.5 ml of reservoir
solution). PurifiedTtClpPwas concentrated to 9mg/ml.Approximately
1week after setting up crystal plates at 293K, large cube-shaped crystals
were obtained in a condition containing 0.1 M sodium acetate (pH 4.8)
and 30% polyethylene glycol 400 (PEG-400).
To obtain crystals of the TtClpP:bortezomib complex before setting
up crystal plates, 5 ml of a 100 mM bortezomib solution dissolved in
DMSO was added to 45 ml of TtClpP solution (9 mg/ml), resulting
in a final concentration of 10 mM bortezomib and 8.1 mg/ml of
TtClpP. Large brick-shaped crystals of theTtClpP:bortezomib complex
were obtained at 293 K in the same condition as TtClpP [0.1M sodium
acetate (pH 4.8) and 30% PEG-400]. TtClpP crystals were scooped,
transferred to a solution containing 32% PEG-400 and 15% glycerol,
and subsequently flash-cooled in liquid nitrogen. Crystals of the TtClpP:
bortezomib complex were scooped directly from the drops and flash-
cooled in liquid nitrogen. The diffraction data of TtClpP (1.95 Å) and
the TtClpP:bortezomib complex (2.70 Å) were collected at the ID30A-
MASSIF (TtClpP) and ID23-1 MX (TtClpP:bortezomib) beamlines at
the European Synchrotron Radiation Facility (ESRF), Grenoble, France.
The obtained datasets were processed using the XDS package (53).
Structure determination of TtClpP and the TtClpP:
bortezomib complex
Diffraction data for TtClpP were processed in space group C2 (a =
105.98 Å, b = 162.79 Å, c = 107.95 Å, a = g = 90°, b = 116.34°). The
structure was solved by maximum-likelihood molecular replacement
(MR) using Phaser (54) in Phenix (55). The x-ray structure of EcClpP
in complex with ADEP1 was used as a searchmodel [PDB: 3KTI; (56)].
Before running Phaser, side chains of the search model were trimmed
using the Schwarzenbacher (57) side-chain pruningmethod in Sculptor
(Phenix). The resulting MR solution was refined in Phenix using posi-
tional (XYZ) and real-space refinement with noncrystallographic
symmetry (NCS) restraints, occupancy refinement, individual ADP
(atomic displacement parameter) refinement with TLS (translation
liberation screw), and optimized x-ray/stereochemistry and x-ray/
ADP weights. Multiple rounds of refinement in Phenix were followed
by additional manual model building carried out in Coot (58).
Diffraction data for TtClpP:bortezomib were processed in space
group C2221 (a = 135.14 Å, b = 168.74 Å, c = 166.08 Å, a = b = g = 90°).
The structure was solved bymaximum-likelihoodMR using Phaser in
Phenix, taking the refined 1.95-Å TtClpP structure as a search model.
Refinement of the TtClpP:bortezomib structure in Phenix was carried
out using the same strategy as for TtClpP (positional and real-spaceFelix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019refinementwithNCS restraints, occupancy refinement, individual ADP
refinement with TLS, and optimized x-ray/stereochemistry and x-ray/
ADP weights, followed by additional manual model building in Coot).
Isothermal titration calorimetry
The interaction between TtClpP and bortezomib was assessed by
ITC using an Auto-iTC200 microcalorimeter (MicroCal-Malvern
Panalytical, Malvern, UK). Calorimetric titrations were performed
with a 1.4 mM bortezomib solution in the injecting syringe and a
10 mMClpP solution in the calorimetric cell in 50 mMHepes (pH 7.6)
and 50 mM NaCl. All solutions were properly degassed to avoid
bubble formation during stirring. In each titration, a sequence of 19
2-ml injections was programmed, with reference power of 10 mcal/s,
initial delay of 60 s, spacing between injections of 150 s, and stirring
speed of 750 rpm.
The heat evolved after each ligand injection was obtained from
the integral of the calorimetric signal. Experiments were performed
in replicates, and data were analyzed using in-house developed
software implemented in Origin 7.0 (OriginLab, Northampton,
MA). The binding isotherms (ligand-normalized heat as a function
of the molar ratio) were analyzed considering the MWC model for
ClpP, an oligomeric macromolecule consisting of 14 identical sub-
units containing a single ligand-binding site each (52). Nonlinear least
squares regression allows the determination of the following binding
parameters: equilibrium constants (KR, KT, g), enthalpies (DHR, DHT,
DHg), and fraction of active protein (N). A fitting routine was imple-
mented in Origin 7.0 (OriginLab).
MWC model implemented in ITC
The MWC model considers an oligomeric macromolecule consisting
of n identical subunits containing a single ligand-binding site each.
Those subunitsmay adopt two conformations, R (relaxed) andT (tense),
with different ligand-binding affinities (KR > KT). Within a given
oligomer, all subunits exhibit the same conformation and ligand
binding occurs to any subunit independently. However, although
T state predominates initially, as a consequence of the higher ligand-
binding affinity for R conformation, ligand binding will shift the
conformational equilibrium by indirectly eliciting a concerted con-
formational change of all subunits toward R conformation within
the same oligomer at once, resulting in a cooperative binding behavior.
The MWC model can only reproduce positive cooperativity, while the
Koshland-Nemethy-Filmer (KNF) model can reproduce both negative
and positive cooperativities. Both models, MWC and KNF, represent
reduced and limited versions of a general allosteric model (44, 59) that
takes into account all possible conformational states (e.g., mixed con-
formations within a protein oligomer) and all possible liganded states,
but, in practice, they are considerablymore useful andmanageable than
the general allosteric model.
The bindingpolynomial for amacromoleculewithn subunits that can
exist, all at once within a given oligomer, in two different conformations,
R and T, and each subunit with a single ligand-binding site, is given by
Z ¼ ∑ni¼0
½PLi
½P ¼ ∑
n
i¼0
½RLi
½R þ
½TLi
½R
 
ð1Þ
where PLi represents the protein complex with i ligandmolecules bound,
andRLi andTLi refer to the complexes of eacholigomeric conformational
state with i binding sites occupied by ligand molecules. In terms of13 of 18
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 site-specific binding parameters, the MWC binding polynomial is
written as follows
Z ¼ ð1þ KR½LÞn þ gð1þ KT½LÞn
¼ ∑ni¼0
n
i
 
KiR þ gKiT
 ½Li ð2Þ
where KR and KT are the site-specific microscopic intrinsic association
constants for a binding site in a protein subunit in the R and T states,
respectively, with KR > KT, and g is the equilibrium constant for the
conformational equilibrium between the T and R oligomers (g =
[Tn]/[Rn]). Because initially the oligomer in T conformation predomi-
nates, the equilibrium constant g is larger than 1. Each term represents
the binding subpolynomial considering n independent ligand-binding
sites in each conformational state, R and T.
Valuable information can be extracted from the binding polyno-
mial. In particular, the molar fraction of each liganded species
FRLi ¼
n
i
 
KiR½Li
Z
FTLi ¼
n
i
 
gKiT½Li
Z
ð3Þ
The two first derivatives of the binding polynomial relative to ligand
concentration and temperature provide two fundamental quantities, the
average number of ligandmolecules bound per oligomericmacromolecule
nLB ¼ 〈i〉 ¼ ∂lnZ∂ln½L ¼
n
Z

KR½L

1þ KR½L
n1þ
gKT½L

1þ KT½L
n1 ð4Þ
that can be expressed more conveniently as
nLB ¼ 〈i〉 ¼ ∂lnZ∂ln½L ¼
1
Z
∑ni¼0
n
i
 
i KiR þ gKiT
 ½Li 
¼ ∑ni¼0iFRLi þ∑
n
i¼0iFTLi ð5Þ
and the average molar excess binding enthalpy
〈DH〉 ¼ RT2 ∂lnZ
∂T
¼ 1
Z

nKR½Lð1þ KR½LÞn1DHR
þ gð1þ KT½LÞnDHg þ ngKT½Lð1þ KT½LÞn1DHT

ð6Þ
that can also be expressed more conveniently as
〈DH〉 ¼ RT2 ∂lnZ
∂T
¼ 1
Z
∑ni¼0
n
i
 
KiR½LiiDHR þ gKiT½LiðDHg þ iDHTÞ
 
¼ ∑ni¼0FRLi iDHR þ ∑
n
i¼0FTLiðDHg þ iDHTÞ ð7Þ
where DHR and DHT are the site-specific microscopic intrinsic ligand-
binding enthalpies for a binding site in a protein subunit in the R and T
states, respectively, and DHg is the enthalpy associated to the concerted
conformational change between the R and T states.Felix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019The binding equations corresponding to the binding equilibrium
derive from the mass conservation and the chemical equilibrium
½PT ¼ ½PZ
½LT ¼ ½L þ ½PTnLB ¼ ½L þ ½PT
∂lnZ
∂ln½L
ð8Þ
The last equation can be transformed into a (n + 1)th-degree
polynomial equation in [L] (in this case, a 15th degree polynomial
equation) with coefficients that are functions of KR, KT, g, [P]T, and
[L]T and that can be solved numerically (e.g., Newton-Raphson
method) for the unknown [L]. Equation 8 must be solved for each
experimental point in the calorimetric titration (i.e., each ligand
injection j), for which the total concentrations of protein and ligand
after each injection j are calculated as follows
½PT; j ¼ ½P0 1
v
V0
 j
½LT; j ¼ ½L0 1 1
v
V0
 j ! ð9Þ
where [P]0 is the initial macromolecule concentration in the cell, [L]0
is the ligand concentration in the syringe, V0 is the calorimetric cell
volume, and v is the injection volume. Once the free ligand concen-
tration is known, the concentration of each complex after each
injection can be calculated (subscript j omitted for the sake of clarity)
½RLi ¼ ½PTFRLi ¼ ½PT
n
i
 
KiR½Li
Z
½TLi ¼ ½PTFTLi ¼ ½PT
n
i
 
gKiT½Li
Z
ð10Þ
The heat effect, qj, associated with each injection j is calculated,
considering that it reflects the change in the average excess molar
binding enthalpy or in the concentration of all complexes in the cal-
orimetric cell between injection j and j − 1
qj ¼ V0 ½PT; j〈DH〉j  ½PT; j1〈DH〉j1 1
v
V0
  
¼ V0 ½PT;j
1
ð1þ KR½LjÞn þ gð1þ KT½LjÞn

nKR½Ljð1þ KR½LjÞn1
 
DHR þ gð1þ KT½LjÞnDHg þ ngKT½Ljð1þ KT½LjÞn1DHT


½PT; j1
1
ð1þ KR½Lj1Þn þ gð1þ KT½Lj1Þn
nKR½Lj1ð1þ KR½Lj1Þn1DHR þ gð1þ KT½Lj1Þn
DHg þ ngKT½Lj1ð1þ KT½Lj1Þn1DHT

1 v
V0
 !
¼ V0
 
½PT;j∑
n
i¼0

FRLi; jiDHR þ FTLi; jðDHg þ iDHTÞ


½PT;j1∑
n
i¼0ðFRLi; j1iDHR þ FTLi; j1ðDHg þ iDHTÞÞ 1
v
V0
 !
¼ V0
 
∑ni¼0 iDHR ½RLij  ½RLij1 1
v
V0
  
þ

ðDHg þ iDHTÞ ½TLij  ½TLij1 1
v
V0
  !
ð11Þ14 of 18
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 Last, qj is normalized by the amount of the ligand injected during
each injection, and an adjustable parameter qd accounting for the
background injection heat (due to solution mismatch, turbulence,
etc.) is also included
Qj ¼
qj
v½L0
þ qd ð12Þ
In addition, a normalizing parameter N is included in Eq. 9 by
multiplying [P]0 to account for the active or binding-competent frac-
tion of macromolecule (percentage of protein able to bind ligand).
Nonlinear least squares regression allows the determination of
the binding parameters KR, KT, g, DHR, DHT, DHg, N, and qd. A
fitting routine was implemented in Origin 7.0 (OriginLab).
For the sake of simplicity, a non-normalized binding polynomial
has been used in Eq. 2, where only the ligand-free R state has been
taken as the reference state. A renormalized binding polynomial can
be constructed taking the subensemble of ligand-free states, R and T,
as the reference (ensemble) state, resulting in a standard binding
polynomial with a leading term equal to 1 when grouping terms
according to powers in [L]. The new binding polynomial is given by
Z* ¼ Z
1þ g ¼
1
1þ g ð1þ KR½LÞ
n þ g
1þ g ð1þ KT½LÞ
n ð13Þ
and the only difference in the subsequent development is that a dif-
ferent reference value for the excess average ligand-binding enthalpy
is used
〈DH*〉 ¼ 〈DH〉  g
1þ g DHg ð14Þ
The second term in the right-hand side of Eq. 14 after the minus
sign is a constant value equal to the average excess enthalpy of the
non-liganded fraction of protein (i.e., ligand-free R and T states)
〈DH*〉 ¼ 〈DH〉  〈DH〉RþT ð15Þ
Thus, that term introduces a shift in the enthalpy scale, and an
additional constant term in the average excess molar enthalpy makes
no difference when calculating the heat effect for each injection, as
can be easily proven
qj ¼ V0 ½PT;j〈DH〉j  ½PT;j1〈DH〉j1 1
v
V0
  
¼ V0½PT;jð〈DH〉j  〈DH〉j1Þ
¼ V0½PT;jð〈DH*〉j  〈DH*〉j1Þ ð16Þ
A nested MWC cooperativity model for the behavior of ClpP in
which each heptamer might undergo a specific concerted conforma-
tional change could have been applied to ClpP but that would have
added three additional equilibrium constants and three additional
enthalpy changes, which would result in overparameterization in
the fitting function and correlation/dependency between fitting
parameters. In addition, the KNF cooperativity model in which se-
quential conformational changes are occurring as the oligomer is be-Felix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019ing occupied by the ligand could have been applied to ClpP, but,
again, more parameters should have been considered in the fitting
function, resulting in overparameterization. Besides, the KNFmodel
cannot reproduce the activation effect induced by bortezomib be-
cause, in the KNF model, the conformational change induced by
the ligand is specifically restricted to those subunits binding the lig-
and, with no possibility of ligand-free subunits undergoing the acti-
vating conformational change. Thus, the MWC cooperativity model
is the minimal model able to reproduce the behavior of ClpP.
The concentration (and the evolution along a titration) of the
different protein species (R and T conformations) can be readily
calculated from the previous equations. The total fractions of pro-
tein subunits in the conformation R or T, FR,T and FT,T, respectively,
are given by
FR;T ¼ ð1þ KR½LÞ
n
Z
¼ 1
Z
∑ni¼0
n
i
 
KiR½Li ¼ ∑
n
i¼0FRLi
FT;T ¼ gð1þ KT½LÞ
n
Z
¼ 1
Z
∑ni¼0
n
i
 
gKiT½Li ¼ ∑
n
i¼0FTLi ð17Þ
and the fractions of protein subunits in the conformation R or T that
are bound to the ligand, FR,B and FT,B, respectively, are given by
FR;B ¼ KR½Lð1þ KR½LÞ
n1
Z
¼ 1
nZ
∑ni¼0
n
i
 
iKiR½Li ¼
1
n
∑ni¼0iFRLi
FT;B ¼ gKT½Lð1þ KT½LÞ
n1
Z
¼ 1
nZ
∑ni¼0
n
i
 
gKiT½Li ¼
1
n
∑ni¼0iFTLi
ð18Þ
The fractions of ligand-free protein subunits in the conforma-
tion R or T, FR,F and FT,F, respectively, can be calculated as the fol-
lowing differences
FR;F ¼ FR;T  FR;B ¼ ð1þ KR½LÞ
n1
Z
¼ ∑ni¼0FRLi 
1
n
∑ni¼0iFRLi
FT;F ¼ FT;T  FT;B ¼ gð1þ KT½LÞ
n1
Z
¼ ∑ni¼0FTLi 
1
n
∑ni¼0iFTLi
ð19Þ
MD simulations
Computational assays
The 3D structure used in the simulations was obtained from TtClpP:
peptide, which corresponds to an extended conformation of the pro-
tein, bereft of substrate. The missing N-terminal b-hairpin residues
were added using Modeller 9.17 (60). Positioning of the seven loops
was done concomitantly for each of the upper and the lower hemi-
spheres of the protein. For the protein with bound peptide substrates,
use was made of the TtClpP:peptide structure featuring stretches of
electron density characteristic of short peptides, over which zwitter-
ionic alanine tripeptides were superimposed. The computational as-
says consisted of the extended TtClpP, with or devoid of alanine
tripeptides bound to the 14 serine active sites of the protein, immersed
in a bath of 75,307watermolecules, with a 0.16MNaCl concentration
corresponding to a cubic simulation cell of length equal to 138 Å at
thermodynamic equilibrium.15 of 18
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 MD protocol
All the MD simulations reported in this study were performed using
NAMD 2.12 (61), with the CHARMM36 (62) force field for proteins
and lipids, and the TIP3P water model. A Langevin thermostat with
a damping coefficient of 1 p s−1 maintained the temperature at 27°C.
The Langevin piston method was used to keep the computational
assay at a nominal pressure of 1 atm. Covalent bonds involving hy-
drogen atoms were constrained to their equilibrium length by the
Rattle algorithm. The Settle algorithm was used to constrain water
molecules to their equilibrium geometry. Long-range electrostatic
forces were evaluated using the particle mesh Ewald algorithm with
a grid spacing of 1.2 Å, while a smoothed 12-Å spherical cutoff was
applied to truncate short-range van der Waals and electrostatic in-
teractions. The r-RESPA multiple time-stepping algorithm com-
bined with a mass-repartitioning scheme was used to integrate the
equations ofmotion with an effective time step of 4 fs for short-range
interactions and of 8 fs for long-range electrostatic interactions.
Simulation design
The extended apo-TtClpP was probed in a 1-ms MD simulation. In
addition, the computational assay consisting of the protein with
zwitterionic alanine tripeptides bound to its 14 serine active sites was
examined in three independent, 1-ms MD simulations, using distinct
initial conditions. These simulations are aimed at exploring how the
presence of the substrate affects the flexibility of TtClpP, alongside
the relevance of the alanine tripeptide as a proxy for the peptide chain
that binds to the Ser97 active site.
Near-equilibrium pulling experiments
To address how the occupancy of the serine active sites of TtClpP
affects the compressibility of TtClpP, we have examined the confor-
mational transition of the protein from its extended state to its com-
pressed state by means of near-equilibrium pulling experiments.
Toward this end, a steeredMDprotocol was used, pulling at constant
velocity a stiff spring of force constant equal to 100 kcal/mol Å. The
transition coordinate was defined as the Euclidian distance separating
the center of mass of the upper hemisphere to that of the lower hemi-
sphere computed from the position of alla-carbon atoms. The length of
the transition coordinate was determined on the basis of apo-TtClpP
and the structure of the compressed conformation (PDB: 3QWD),
and amounts to 8 Å. Three independent, 200-ns-long realizations were
performed for the empty protein and three trajectories for ClpP
containing either two (in one trajectory) or three (in the other trajec-
tories) zwitterionic alanine tripeptides, pulling irreversibly the two lobes
of the protein from an extended state to a compressed one.
Multi-angle laser light scattering
SEC-MALLS experiments were conducted at room temperature on
a high-performance liquid chromatography (HPLC) system consisting
of a DGU-20 AD degasser, an LC-20 AD pump, a SIL20-ACHT auto-
sampler, a CBM-20A communication interface, an SPD-M20AUV-Vis
detector (Shimadzu, Kyoto, Japan), an XL-Therm column oven
(WynSep, Sainte Foy d’Aigrefeuille, France), and static light scattering
miniDAWN Treos, DLS DynaPro NANOSTAR, and refractive index
Optilab rEX detectors. Data were analyzed using version 5.4.3.20 of
the ASTRA software (Wyatt Technology, Santa Barbara, USA). TtClpP
(1 mg/ml, 100 ml) was injected at 0.5 ml/min on a Superdex 200 10/300
GL column (GE Healthcare), equilibrated with a buffer containing
100mM tris (pH 8.5), 100 mMNaCl, and 5% glycerol. Bovine serumFelix et al., Sci. Adv. 2019;5 : eaaw3818 4 September 2019albumin at 2 mg/ml in phosphate-buffered saline (PBS) buffer was
injected as a control in each experiment. The extinction coefficient
and refractive index increments for the proteins were calculated from
the amino acid sequences using the program SEDFIT.
Dynamic light scattering
TtClpP (3 mM) in a buffer containing 100 mM tris (pH 8.5), 100 mM
NaCl, and 5% glycerol without or with 5 mM added bortezomib was
measured using a DynaPro NANOSTAR (Wyatt, Santa Barbara,
USA) instrument operated at 25° or 45°C and analyzed with the as-
sociated DYNAMICS software. Each experiment was performed in
triplicate (three times for each of two TtClpP samples, both measured
at 25° and 45°C), and hydrodynamic radii were calculated as the av-
erage of these replicates. Theoretical hydrodynamic radii of com-
pressed TtClpP [based on PDB: 3QWD (18)] and extended TtClpP
(using the TtClpP:bortezomib structure), after modeling of missing
residues in the N-terminal b-hairpins and the N and C termini using
SWISS-MODEL (63), were calculated using Hydropro10 (64) using
a solvent viscosity and a solvent density of 0.0010387 poise and
1.0114 g/cm3, respectively (5% glycerol, 25°C), or 0.00068656 poise
and 1.0043 g/cm3, respectively (5% glycerol, 45°C).SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/9/eaaw3818/DC1
Fig. S1. Biochemical characterization of TtClpP.
Fig. S2. Characterization of GFPssrA degradation by TtClpXP.
Fig. S3. Characterization of TtClpP peptidase activity in the absence and presence of
bortezomib.
Fig. S4. Characterization of FITC-casein degradation by TtClpP in the absence and presence of
bortezomib and/or TtClpX.
Fig. S5. Ligand validation by 2mFo-DFc, omit, and polder maps.
Fig. S6. Distance RMSD of the 14 alanine tripeptide ligands with respect to their initial bound
state in TtClpP for three independent, 1-ms-long MD simulations.
Fig. S7. Analysis of structural differences between TtClpP and EcClpP.
Table S1. Crystallographic data collection and refinement statistics.
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